logo
You're Great At Your Job, Why Aren't You Getting Hired?

You're Great At Your Job, Why Aren't You Getting Hired?

Forbes5 hours ago
You've never been shy about working hard, and it shows. You're the go-to person at work. The one your clients trust to get things done. The leader your team looks to for next steps. You don't mind putting in the time, effort, and energy to succeed in your career.
But now that you're ready for a new job elsewhere, you can hardly land an interview. And, the few interviews you have landed always seem to go nowhere. You can't help but wonder if it's the economy, the job market, or maybe even you.
But, here's something you may not have considered: the skills that help you succeed on the job are not the same skills that will help you get hired. Landing a new job requires you to operate differently than you're used to in your current role. Here are four signs you're relying on the wrong skills to land your next job.
You're Good at Everything & Can't Decide What's Next
As a top performer at work, you're likely used to tackling whatever gets thrown your way. That random fire before product launch day? You're on it. Need to secure a new partnership before the end of Q3? Handled. You're the person others trust to get anything and everything done. Still, while you're great at many things, you haven't stopped to ask yourself, 'What do I really want to do next?' Being good at your job can increase your visibility at work. But without clear direction, you'll end up with a scattered job search that doesn't help you land job offers.
You're Hoping Your Track Record Will Speak for You
Being a high-achiever comes with its perks. Eventually, your team and colleagues start to notice the projects you've worked on and the results you've delivered without you having to say much. Your success may even lead to a promotion or an unexpected raise. But when searching for your next career move, it hardly works the same way. Unlike in the office, where you're surrounded by familiar faces, landing your next role requires you to position your skills, experience, and results in front of strangers. You can't afford to wait for your track record to speak for you. You have to speak about it. It's a skill you may not have much practice with, but it's one you'll need if you want to land a role where you're truly valued.
You Struggle to Own Your Impact
Because you're naturally good at your job, it's easy to overlook the importance of the work you do. Maybe you brush it off when your manager celebrates you in a team meeting. Or, perhaps you give credit to the entire team without acknowledging your own contributions, even silently. You might be able to get by downplaying your impact when you're coasting at work, but not when you're ready for a new job. When you overlook your value, others tend to do the same. That doesn't mean you have to be the loudest in the room. But you do need to own what makes you credible, capable, and trusted to solve real problems.
You Have a Plan for Everything, Except This
Would your friends describe you as ambitious, driven, and organized? Do you like to have a plan for everything, even if it's just a rough draft in your head? If so, one of the main reasons you might be struggling to get hired, despite your qualifications, is because you don't have a clear strategy for landing your next role. At work, it's easy to rely on your manager or senior leadership to set the direction for the next quarter or fiscal year. But, in your job search, you have to get in the driver's seat and decide on the best route to get where you want to go. You can't wait for recruiters or referrals to fall in your lap. Like everything else you do, you need a strategy that gets you noticed and puts you in control of your next move.
You already know how to succeed on the job. But, getting the next one? That requires a different set of skills. It starts with clarity on what you want, confidence in what you bring, positioning that helps you stand out, and a strategy that actually works in today's market. Adunola Adeshola coaches high-achievers on how to land new jobs they love without endlessly applying, starting over or settling for less. She shares more career insights on The Level Up Podcast.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Hudbay Minerals (HBM) Climbs 15% on Stellar Earnings, $600-Million Investment From Mitsubishi
Hudbay Minerals (HBM) Climbs 15% on Stellar Earnings, $600-Million Investment From Mitsubishi

Yahoo

time20 minutes ago

  • Yahoo

Hudbay Minerals (HBM) Climbs 15% on Stellar Earnings, $600-Million Investment From Mitsubishi

We recently published . Hudbay Minerals Inc. (NYSE:HBM) is one of the best-performing stocks on Wednesday. Hudbay Minerals grew its share prices for a second day on Wednesday, up 15.03 percent to close at $11.33 apiece, following an impressive earnings performance and a $600-million investment from Mitsubishi Corp. In its updated report, Hudbay Minerals Inc. (NYSE:HBM) said it swung to a net income attributable to shareholders of $117.7 million from an attributable net loss of $16.5 million in the same period last year, driven by higher gross margins and strong cost control. Revenues increased by 26 percent to $536.4 million from $425.5 million year-on-year. 'With the strong performance in the first half of the year, we are reaffirming our full year consolidated production guidance and are favourably tracking well below our full year consolidated cost guidance for 2025,' said Hudbay Minerals Inc. (NYSE:HBM) President and CEO Peter Kukielski. For the full-year period, the company is targeting to produce between 117,000 and 149,000 tons of copper, as well as 247,500 to 308,000 ounces of gold. In other news, Hudbay Minerals Inc. (NYSE:HBM) was able to raise $600 million in fresh funds from Mitsubishi Corp. after the latter acquired a 30-percent stake in Copper World LLC. Under the agreement, Mitsubishi will pay an upfront cash of $420 million, with the balance to serve as a matching contribution within an 18-month period. While we acknowledge the potential of HBM as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the . Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Paramount Skydance (PSKY) Soars 60% to New High. Time to Book Gains?
Paramount Skydance (PSKY) Soars 60% to New High. Time to Book Gains?

Yahoo

time20 minutes ago

  • Yahoo

Paramount Skydance (PSKY) Soars 60% to New High. Time to Book Gains?

We recently published . Paramount Skydance Corp. (NASDAQ:PSKY) is one of the best-performing stocks on Wednesday. Paramount Skydance extended its rally to touch a new high on Wednesday, finishing up by 36.74 percent at $15 apiece, with a former hedge fund manager calling it a 'meme' stock. In a social media post, Mad Money host and former hedge fund manager Jim Cramer said Paramount Skydance Corp. (NASDAQ:PSKY) is a 'meme stock' given the company's small public float and unjustifiable rally amid the lack of fresh developments. Paramount Skydance Corp. (NASDAQ:PSKY) climbed by as high as 60 percent at intra-day trading to hit $17.53 before paring gains to finish slightly lower during the session. In recent news, the company bagged a new $7.7-billion deal to exclusively air the Ultimate Fighting Championship (UFC) on Paramount+ for seven years beginning in 2026. The deal would include UFC's full slate of 13 marquee numbered events and 30 Fight Nights through its direct-to-consumer streaming platform, Paramount+, with select numbered events to be simulcast on CBS. cellanr, CC BY-SA 2.0 , via Wikimedia Commons As part of the agreement, Paramount Skydance Corp. (NASDAQ:PSKY) will move UFC away from the existing Pay-Per-View model and make the latter available at no additional cost to Paramount+ subscribers in the US. It also intends to explore UFC rights outside the US in the future. While we acknowledge the potential of PSKY as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the . Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

ImmunityBio (IBRX) Jumps 14% as on Promising Therapy Candidate Results
ImmunityBio (IBRX) Jumps 14% as on Promising Therapy Candidate Results

Yahoo

time20 minutes ago

  • Yahoo

ImmunityBio (IBRX) Jumps 14% as on Promising Therapy Candidate Results

We recently published . ImmunityBio, Inc. (NASDAQ:IBRX) is one of the best-performing stocks on Wednesday. ImmunityBio soared by 14.17 percent on Wednesday to close at $2.82 apiece as investors cheered promising early findings from its ongoing trial (QUILT-106) to treat a rare blood cancer type with its therapy candidate. In a statement, ImmunityBio, Inc. (NASDAQ:IBRX) said the first phase of QUILT-106 showed highly promising results in the first two patients with Waldenstrom macroglobulinemia (WM)—a type of non-Hodgkins lymphoma (NHL)—using its CD19 CAR-NK (CD19 t-haNK) natural killer cell therapy. The trial aims to evaluate the safety and efficacy of the cell therapy alone, as well as when it is combined with an existing drug called rituximab. According to ImmunityBio, Inc. (NASDAQ:IBRX), both patients tolerated the therapy candidate without any significant side effects. Notably, all infusions were administered in an outpatient setting. Copyright: katrintimoff / 123RF Stock Photo 'One patient achieved a complete response (CR) with CD19 CAR NK monotherapy, while the second patient achieved CR with CD19 CAR-NK in combination with rituximab. Remission was maintained and is ongoing for six months to date,' ImmunityBio, Inc. (NASDAQ:IBRX) said. While we acknowledge the potential of IBRX as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the . Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store